Whistleblowers
Subtitle: incentives, disincentives, and protection strategies
By: Frederick D. Lipman
Series: Wiley corporate F&A series; Wiley corporate F & A
Publisher: Wiley
Published: 2012
Place of publication: Hoboken, N.J
Language: eng
Number of pages: 272
ISBN-13: 9781118094037
Subjects: Whistle blowing; Law and legislation; Business ethics; Case studies
Description: "The book will discuss business protection strategies and best practices in dealing with whistleblowers, as well as the GlaxoSmithKline, Pfizer and other high profile whistleblower cases. The book is expected to appeal to Board members, C-Suite executives, corporate compliance personnel, attorneys for whistleblowers and defense attorneys as well as all potential employee whistleblowers. The book emphasizes the disincentives to whistleblowing, and will review the academic studies of whistleblowers with the idea of developing best practices to deal with whistleblowers: Introduction. 1. Dodd-Frank Incentives to Whistleblowers 2. The Remarkable Story of Cheryl Eckard and the $96 Million Bounty 3.The Pfizer Over $100 Million Bounty Collectors 4.Other Statutory Incentives to Whistleblowing 5.Disincentives to Whistleblowers and Academic Studies of Whistleblowers 6.Best Practices in Complying with the U. S. Department of Justice Guidelines 7.Best Practices for CEOs in Dealing with Whistleblowers 8.Best Practices for Conducting Whistleblower Investigations 9.The New SEC Whistleblower Rules 10.Qui Tam Actions and Their Defense "--
Notes: Includes bibliographical references and index.
Table of contents: title: Part I; title: The Whistleblowers and the Dodd-Frank Incentives -- -- Chapter 1; title: The Dramatic Expansion of Whistleblower Awards under Dodd-Frank -- 11; title: Whistleblower Provisions of Dodd-Frank -- 13; title: What Is "Original Information"? -- 14; title: What Are Violations of the Federal Securities Laws? -- 15; title: Rule 10b-5: Market Manipulation -- 19; title: Violating the Accounting Standards -- 20; title: False Financial Statements by Public Companies -- 20; title: Other Securities Laws -- 22; title: Protections for Whistleblowers -- 23; title: Commodity Exchange Act -- 23; title: Notes -- 25 -- Chapter 2; title: The Remarkable Story of Cheryl Eckard and the $96 Million Bounty under the False Claims Act -- 27; title: Who Is Cheryl Eckard? -- 27; title: Eckard's Post-termination Activities -- 28; title: Eckard's Superiors -- 29; title: Background Allegations -- 30; title: Alleged Violations -- 31; title: Timeline of Eckard's Alleged Activities -- 33; title: The Lessons of Glaxo -- 40; title: Notes -- 42 -- Chapter 3; title: The Pfizer Whistleblowers Who Collected Over $100 Million under the False Claims Act -- 45; title: John Kopchinski -- 46; title: Bextra -- 47; title: The Complaint -- 48; title: Pfizer Lessons -- 51; title: Notes -- 53 -- Part II; title: Disincentives and Factors Motivating Public Disclosure -- -- Chapter 4; title: Disincentives to Internal Whistleblowers -- 57; title: Financial Disincentives -- 58; title: Nonfinancial Disincentives -- 59; title: Contractual Commitments and Fiduciary Duties -- 60; title: Ethics Resource Center Survey -- 61; title: Reinstatement as a Remedy -- 62; title: Empirical Study -- 65; title: Notes -- 67 -- Chapter 5; title: Women as Whistleblowers: Factors Motivating Public Whistleblowing -- 69; title: Sherron Watkins -- 69; title: Cynthia Cooper -- 71; title: Coleen Rowley -- 71; title: External Reporting by Internal Whistleblowers -- 72; title: Whistleblower Anonymity -- 74; title: Notes -- 74 -- Part III; title: Organizational Best Practices -- -- Chapter 6; title: Why Should Organizations Adopt a Robust Whistleblower System? -- 79; title: Diminishment of Shareholder Wealth -- 80; title: Boards of Directors -- 81; title: We Were Duped! -- 82; title: Executive Whistleblowers -- 84; title: Why Independent Directors Cannot Rely Solely on Independent or Internal Auditors -- 86; title: Legal Standard -- 89; title: Caremark -- 90; title: Recommended Strategy -- 91; title: Criminal Liability of an Organization -- 92; title: Responsible Corporate Officer Doctrine -- 93; title: The Acme Markets Case -- 94; title: The U.S. Department of Justice Criminal Guidelines -- 96; title: The Disadvantages of a Robust Whistleblower System -- 97; title: Notes -- 98 -- Chapter 7; title: Establishing a Robust Whistleblower System -- 103; title: Problems with the Current Whistleblower System -- 104; title: Initial Steps -- 107; title: Elements of a Robust Whistleblower Policy -- 108; title: Independent Directors Must Be in Charge -- 109; title: The Whistleblower Program Must Be Independently Administered -- 111; title: Whistleblower Complaints Should be Investigated by Independent Counsel Reporting Directly to the Independent Directors -- 113; title: There Should Be No Presumption that Anonymous Complaints Are Less Deserving of Investigation -- 117; title: Motivations and Personality of the Whistleblower Are Not Relevant to the Truth of the Allegations -- 118; title: Absolute Protection of Whistleblowers' Identity Is Essential -- 119; title: Assess the Effectiveness of Hotlines and Provide Employee Compliance Training -- 123; title: Independent Counsel Should Report the Status and Results of the Investigation -- 124; title: Internal Whistleblowers Should Receive Meaningful Monetary Rewards -- 125; title: The Whistleblower Policy Must Be Communicated Effectively -- 127; title: There Should Be Milder Sanctions for Whistleblowers Involved in Illegal Group Activity -- 130; title: Retaliation Claims Should Be Independently Investigated -- 131; title: The Director of Corporate Compliance Should Become the Eyes and Ears of the Independent Directors -- 132; title: Major Dos and Don'ts for CEOs -- 134; title: Notes -- 135 -- Part IV; title: Statutory Incentives and Sec Award Regulations -- -- Chapter 8; title: The False Claims Act: Qui Tarn Cases -- 141; title: What Is a False Claim? -- 142; title: False Claims Act Bounties -- 144; title: U.S. Department of Justice Memorandum -- 146; title: Statute of Limitations -- 149; title: Notes -- 150 -- Chapter 9; title: IRS Whistleblowers -- 153; title: Section 7623(b): Mandatory Whistleblower Awards -- 155; title: Reduction of Award Percentage -- 156; title: Section 7623(a): Discretionary Awards -- 157; title: Form 211 -- 158; title: IRS Whistleblowers Awards -- 159; title: IRS Award Determinations -- 160; title: Award Administrative Proceedings -- 162; title: Appeal to Tax Court -- 164; title: Duration of Process and Award Payment -- 164; title: Confidentiality of Whistleblower -- 165; title: Right to Counsel -- 165; title: IRS Contracts -- 165; title: Disqualification of U.S. Treasury Department Federal Employees -- 166; title: Notes -- 167 -- Chapter 10; title: Other Statutory Incentives and Protections for Whistleblowers -- 169; title: Act to Prevent Pollution from Ships -- 169; title: False Patent Marking Statute -- 170; title: U.S. Tariff Act of 1930 -- 172; title: State False Claims Statutes -- 173; title: Whistleblower Protections -- 179; title: Barker v. UBS -- 180; title: Other Statutory Whistleblower Protections -- 185; title: Notes -- 186 -- Chapter 11; title: A Step-by-Step Guide to SEC Whistleblowers Awards under Dodd-Frank -- 189; title: Summary -- 190; title: SEC Investor Protection Fund -- 194; title: Does the Whistleblower Need an Attorney? -- 195; title: Step-by-Step Guide -- 196; title: Determining Whether the Over $1 Million Threshold Is -- 202; title: Satisfied Determining the Amount of an Award -- 202; title: Must an Employee Comply with the Company's Internal Compliance Program? -- 204; title: Confidentiality -- 205; title: Nonwaiver of Whistleblower Rights -- 205; title: Appeals -- 205; title: Anti-retaliation Provision -- 206; title: Notes-- 206.